How the QALY Harms People with CF – Ari Ne’eman (Audio)

As the use of quality adjusted life years (QALYs) is increasingly suggested as a method to determine drug pricing, it is vital to understand the flaws in this methodology, and how it harms the CF community by devaluing the lives of those with disease, dismissing the value of new medications, and ultimately, interfering with access to new therapies. In this podcast, Ari Ne’eman, a consultant to the Partnership to Improve Patient Care (www.pipcpatients.org/), provides an extremely insightful overview of QALY, and the impact of ICER in applying this to its recent evaluation of Trikafta. While there is specific focus on CF, the information contained in the video applies to all disease groups.

CF Community Voices is generously sponsored by Vertex Pharmaceuticals, Genentech, Chiesi USA, and Gilead Sciences.